Cochranized in the past, macrolides (usually azithromycin) seem more convincingly beneficial regarding mortality and treatment failure in pneumonia (especially in the elderly). This large but retrospective VA registry analysis supports this suggestion. The finding of more MIs but fewer ‘cardiac events’ is confusing. First line for everyone, include it in the initial antimicrobials, continue it despite negative atypical screen, avoid in ischaemic heart disease – I don’t think we know yet.
Macrolides still look good for pneumonia
-
June 23, 2014
FOAMcc search (ICM/EM sites)
LITFL
- Funtabulously Frivolous Friday Five 358 April 19, 2024
- Top 10 AI Courses for Clinicians April 19, 2024
- Emergency Procedure: Postpartum haemorrhage April 5, 2024
- Rutherford Morison April 1, 2024
- AI Tools for Learning March 25, 2024
Wessex ICS BottomLine
- Validation of the MIRACLE 2 Score for Prognostication After OOHCA March 22, 2024
- Critical Care Evidence Updates – February 2024 March 22, 2024
- Emergency Evidence Updates – February 2024 March 22, 2024
- ARiE Trial – Rifaximin for encephalopathy March 1, 2024
- Critical Care Evidence Updates – January 2024 February 23, 2024
Emcrit
- EMCrit 373 – Mike Weinstock with another Critical Care Bounceback: “Asymptomatic Hypertension” April 18, 2024
- Pulmcrit wee: The cutoff razor April 15, 2024
- EMCrit Wee – Ross Prager on 10 Heuristics for the New ICU Attending April 13, 2024
- EMCrit 372 – FoundStab Intubation SOP April 5, 2024
- EMCrit RACC-Lit Review – March 2024 March 28, 2024
Past posts
Post categories
RSS Error: WP HTTP Error: A valid URL was not provided.
RSS Error: WP HTTP Error: A valid URL was not provided.